Drug Therapy
Perspectives
2019 at a glance: Hem-onc U.S. drug approvals
A reference guide for the latest drug approvals in hematology and oncology, including biosimilars.
News
FDA approves diroximel fumarate for relapsing MS
The oral drug, marketed as Vumerity, converts to the same active metabolite as dimethyl fumarate.
Conference Coverage
SUSTAIN 10: Weight loss, glycemic control better with semaglutide than liraglutide
BARCELONA – Once-weekly treatment with subcutaneous semaglutide yielded greater reductions in HbA1c and body weight than once-daily...
News
FDA approves onabotulinumtoxinA for pediatric lower limb spasticity
The indication excludes spasticity related to cerebral palsy.
News
Hematopoietic cell transplant offers realistic cure in secondary AML
The observational trial showed that survival was significantly higher with transplant than with chemotherapy consolidation therapy in patients...
News
FDA approves Trikafta for treatment of cystic fibrosis
This drug makes treatment available to most cystic fibrosis patients, including adolescents.
News
Drug crisis continues to evolve beyond opioids
Primary care physicians “are well intentioned but underprepared and may miss some of the drug misuse risks affecting their patients,” says the...
Latest News
Dapagliflozin approved for reducing HF hospitalization in diabetes
It is the first SGLT2 inhibitor approved in the United States for this indication in adults with type 2 disease.
Conference Coverage
Certain diabetes drugs may thwart dementia
COPENHAGEN – Intriguing findings from a Danish national registry study.
Conference Coverage
Primary periodic paralysis attacks reduced with long-term dichlorphenamide
AUSTIN, TEX. – The majority of paresthesia and cognition-related adverse events were mild or moderate with few participants discontinuing the...